With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration. GSK will make an equity investment in CureVac of 130 million pounds, ...

The company has also worked to make R&D more efficient by laying off more than 25% of the R&D staff since 2006. The company also reduced lab space by more than 15%.

GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth - Creates world's first R&D Open Lab to increase ...

GlaxoSmithKline (GKS, London) outlined a plan to invest EUR 500 million ($649 million) in research and development (R&D) and related manufacturing in the United Kingdom conditioned on the successful ...

By Maggie Fick and Natalie Grover. LONDON, April 26 (Reuters) - British drugmaker GSK on Wednesday warned that the overhaul of laws governing the EU's pharmaceuticals industry risks forcing ...

It looks like GSK may have found its blockbuster. Arexvy, the world’s first RSV vaccine for older adults has been approved in the U.S. and Japan.

Atria Investments Inc’s holdings in GSK were worth $1,254,000 as of its most recent SEC ... Commercial Operations and Total R&D. Read More. Five stocks we like better than GSK; Uptrend Stocks ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.